Metformin and Rifampicin combination augments active to latent tuberculosis conversion: A computational study

Area of Science:

• Molecular biology
• Computational biology
• Infectious diseases

Background:

• Tuberculosis (TB) is a global infectious disease exacerbated by drug-resistant strains.
• Latent tuberculosis, a dormant state of Mycobacterium tuberculosis, hinders eradication efforts.
• Diabetes mellitus is a risk factor for TB, and metformin may impact active TB treatment.

Purpose of the Study:

• To investigate the molecular mechanisms of latent tuberculosis.
• To determine the effect of combining metformin with rifampicin on latent tuberculosis.
• To explore the interaction of metformin and rifampicin with the DosR regulatory machinery.

Main Methods:

• Computational biology tools were employed.
• The study focused on the DosR transcription factor and its associated machinery.
• Molecular interactions between metformin, rifampicin, and the DosR-DNA complex were analyzed.

Main Results:

• Metformin binding to the DosR-DNA complex was investigated.
• The potential interaction of rifampicin with the metformin-bound DosR-DNA complex was modeled.
• Results suggest that this interaction could lead to the conversion of active TB to latent TB.

Conclusions:

• The combination of metformin and rifampicin may influence the transition between active and latent tuberculosis.
• Understanding these molecular interactions is crucial for developing new strategies against tuberculosis.
• Further research is warranted to validate these computational findings in vitro and in vivo.